Recently, genomic discoveries have led to the development of a plethora of genomic markers which aid in risk stratifying PCa patients such as prostate cancer antigen 3 (PCA3) and transmembrane protease, serine avian erythroblastosis virus E26 oncogene homolog gene fusions (TMPRSS2:ERG) [22]. The gene discussed is PCA3; the disease is posterior cortical atrophy.